(NYSE: AZN) Astrazeneca's forecast annual revenue growth rate of 7.38% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Astrazeneca's revenue in 2026 is $58,127,000,000.On average, 28 Wall Street analysts forecast AZN's revenue for 2026 to be $99,024,850,000,000, with the lowest AZN revenue forecast at $87,472,700,000,000, and the highest AZN revenue forecast at $105,865,000,000,000. On average, 26 Wall Street analysts forecast AZN's revenue for 2027 to be $104,776,900,000,000, with the lowest AZN revenue forecast at $92,114,950,000,000, and the highest AZN revenue forecast at $114,138,900,000,000.
In 2028, AZN is forecast to generate $111,902,250,000,000 in revenue, with the lowest revenue forecast at $96,044,200,000,000 and the highest revenue forecast at $124,500,650,000,000.